A 1238-gene solid tumor panel is among the broadest available profiling assays, and breadth raises the stakes for quality. With so many regions read at once, the credibility of every result depends on the laboratory's validation and accreditation, not just the gene count on the package. Buyers should treat accreditation as the primary selection filter.
Regulatory confidence comes from documented validation: the lab proves limit of detection for low-frequency variants, establishes sensitivity and specificity against reference samples, and controls contamination through unique dual indexing. Accredited facilities follow written standard operating procedures for every step from extraction to sign-out, and they participate in external proficiency testing.
The panel serves complex or refractory solid tumors where maximal genomic coverage may reveal a rare actionable event or a trial match. Because reporting spans many genes, the laboratory must classify variants consistently using an accepted framework to avoid ambiguous guidance.
Source only from laboratories that disclose their accreditation status and validation summaries. A credible vendor explains how variants are tiered and how uncertain findings are communicated, rather than presenting an unqualified long list.
Ship specimens at 2–8°C with leak-proof packaging and confirm the lab's chain-of-custody process. GIVE LIFE TIME International prioritizes profiling partners that publish accreditation and QC metrics for buyer review.
Before committing volume, request the laboratory's validation package: limit of detection for low-frequency variants, sensitivity and specificity against reference materials, and its external proficiency-testing record. These documents let a procurement team compare vendors on evidence rather than marketing claims. Confirm the report states the accreditation body and the version of the variant-classification guideline used, because inconsistent frameworks make cross-lab comparison difficult. A transparent lab will also disclose how inconclusive findings are handled, which matters when a 1238-gene result returns few clear drivers. Set the turnaround expectation in writing and verify chain-of-custody steps for every specimen received.
Request a sample de-identified report so the buyer can review layout before signing volume.
Q: What accreditation should a 1238-gene lab hold?
Recognized molecular laboratory accreditation plus documented external proficiency testing.
Q: How is assay quality proven before use?
Through limit-of-detection, sensitivity, and specificity validation against reference materials.
Q: Why does gene count alone not guarantee reliability?
Result trust depends on validation and accreditation, not merely the number of genes sequenced.
A 1238-gene solid tumor panel is among the broadest available profiling assays, and breadth raises the stakes for quality. With so many regions read at once, the credibility of every result depends on the laboratory's validation and accreditation, not just the gene count on the package. Buyers should treat accreditation as the primary selection filter.
Regulatory confidence comes from documented validation: the lab proves limit of detection for low-frequency variants, establishes sensitivity and specificity against reference samples, and controls contamination through unique dual indexing. Accredited facilities follow written standard operating procedures for every step from extraction to sign-out, and they participate in external proficiency testing.
The panel serves complex or refractory solid tumors where maximal genomic coverage may reveal a rare actionable event or a trial match. Because reporting spans many genes, the laboratory must classify variants consistently using an accepted framework to avoid ambiguous guidance.
Source only from laboratories that disclose their accreditation status and validation summaries. A credible vendor explains how variants are tiered and how uncertain findings are communicated, rather than presenting an unqualified long list.
Ship specimens at 2–8°C with leak-proof packaging and confirm the lab's chain-of-custody process. GIVE LIFE TIME International prioritizes profiling partners that publish accreditation and QC metrics for buyer review.
Before committing volume, request the laboratory's validation package: limit of detection for low-frequency variants, sensitivity and specificity against reference materials, and its external proficiency-testing record. These documents let a procurement team compare vendors on evidence rather than marketing claims. Confirm the report states the accreditation body and the version of the variant-classification guideline used, because inconsistent frameworks make cross-lab comparison difficult. A transparent lab will also disclose how inconclusive findings are handled, which matters when a 1238-gene result returns few clear drivers. Set the turnaround expectation in writing and verify chain-of-custody steps for every specimen received.
Request a sample de-identified report so the buyer can review layout before signing volume.
Q: What accreditation should a 1238-gene lab hold?
Recognized molecular laboratory accreditation plus documented external proficiency testing.
Q: How is assay quality proven before use?
Through limit-of-detection, sensitivity, and specificity validation against reference materials.
Q: Why does gene count alone not guarantee reliability?
Result trust depends on validation and accreditation, not merely the number of genes sequenced.